TY - JOUR
T1 - Akt2 (protein kinase B beta) stabilizes ATP7A, a copper transporter for extracellular superoxide dismutase, in vascular smooth muscle
T2 - Novel mechanism to limit endothelial dysfunction in type 2 diabetes mellitus
AU - Sudhahar, Varadarajan
AU - Okur, Mustafa Nazir
AU - Bagi, Zsolt
AU - O'Bryan, John P.
AU - Hay, Nissim
AU - Makino, Ayako
AU - Patel, Vijay S.
AU - Phillips, Shane A.
AU - Stepp, David
AU - Ushio-Fukai, Masuko
AU - Fukai, Tohru
N1 - Funding Information:
We thank Mr Ronald D. McKinney for editorial assistance. We thank Taplin Mass Spectrometry’s facility for assistance with phosphorylation site determinations. This research was supported by 5NIH R01 HL070187-14 (to T. Fukai), Department of Veterans Affairs Merit Review grant 2I01BX001232-05 (to T. Fukai), R01HL133613, R01HL116976 (to T. Fukai, M. Ushio-Fukai), NIHR01 HL077524, HL077524-S1, R21HL112293 (to M. Ushio-Fukai), HL085614, HL095701, HL130513 (to S.A. Phillips), 11POST5740006 and 15SDG25700406 (to V. Sudhahar). V. Sudhahar designed the study, performed experiments, analyzed data, and wrote the article. M.N. Okur and J.P. O’Bryan performed ubiquitination assay. A. Makino provided some T2DM sample. S.A. Phillips, Z. Bagi, and V.S. Patel provided human biopsy sample. N. Hay provided Akt1 and Akt2 KO mice. D. Stepp provided db/db/PTP1B−/− (protein-tyrosine phosphatase 1B-deficient) mice. M. Ushio-Fukai and T. Fukai designed the overall study, analyzed data, and wrote, reviewed, and edited the article. T. Fukai is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Publisher Copyright:
© 2018 American Heart Association, Inc.
PY - 2018
Y1 - 2018
N2 - Objective-Copper transporter ATP7A (copper-transporting/ATPase) is required for full activation of SOD3 (extracellular superoxide dismutase), which is secreted from vascular smooth muscle cells (VSMCs) and anchors to endothelial cell surface to preserve endothelial function by scavenging extracellular superoxide. We reported that ATP7A protein expression and SOD3 activity are decreased in insulin-deficient type 1 diabetes mellitus vessels, thereby, inducing superoxide-mediated endothelial dysfunction, which are rescued by insulin treatment. However, it is unknown regarding the mechanism by which insulin increases ATP7A expression in VSMCs and whether ATP7A downregulation is observed in T2DM (type2 diabetes mellitus) mice and human in which insulin-Akt (protein kinase B) pathway is selectively impaired. Approach and Results-Here we show that ATP7A protein is markedly downregulated in vessels isolated from T2DM patients, as well as those from high-fat diet-induced or db/db T2DM mice. Akt2 (protein kinase B beta) activated by insulin promotes ATP7A stabilization via preventing ubiquitination/degradation as well as translocation to plasma membrane in VSMCs, which contributes to activation of SOD3 that protects against T2DM-induced endothelial dysfunction. Downregulation of ATP7A in T2DM vessels is restored by constitutive active Akt or PTP1B-/- (protein-tyrosine phosphatase 1B-deficient) T2DM mice, which enhance insulin-Akt signaling. Immunoprecipitation, in vitro kinase assay, and mass spectrometry analysis reveal that insulin stimulates Akt2 binding to ATP7A to induce phosphorylation at Ser1424/1463/1466. Furthermore, SOD3 activity is reduced in Akt2-/- vessels or VSMCs, which is rescued by ATP7A overexpression. Conclusion-Akt2 plays a critical role in ATP7A protein stabilization and translocation to plasma membrane in VSMCs, which contributes to full activation of vascular SOD3 that protects against endothelial dysfunction in T2DM.
AB - Objective-Copper transporter ATP7A (copper-transporting/ATPase) is required for full activation of SOD3 (extracellular superoxide dismutase), which is secreted from vascular smooth muscle cells (VSMCs) and anchors to endothelial cell surface to preserve endothelial function by scavenging extracellular superoxide. We reported that ATP7A protein expression and SOD3 activity are decreased in insulin-deficient type 1 diabetes mellitus vessels, thereby, inducing superoxide-mediated endothelial dysfunction, which are rescued by insulin treatment. However, it is unknown regarding the mechanism by which insulin increases ATP7A expression in VSMCs and whether ATP7A downregulation is observed in T2DM (type2 diabetes mellitus) mice and human in which insulin-Akt (protein kinase B) pathway is selectively impaired. Approach and Results-Here we show that ATP7A protein is markedly downregulated in vessels isolated from T2DM patients, as well as those from high-fat diet-induced or db/db T2DM mice. Akt2 (protein kinase B beta) activated by insulin promotes ATP7A stabilization via preventing ubiquitination/degradation as well as translocation to plasma membrane in VSMCs, which contributes to activation of SOD3 that protects against T2DM-induced endothelial dysfunction. Downregulation of ATP7A in T2DM vessels is restored by constitutive active Akt or PTP1B-/- (protein-tyrosine phosphatase 1B-deficient) T2DM mice, which enhance insulin-Akt signaling. Immunoprecipitation, in vitro kinase assay, and mass spectrometry analysis reveal that insulin stimulates Akt2 binding to ATP7A to induce phosphorylation at Ser1424/1463/1466. Furthermore, SOD3 activity is reduced in Akt2-/- vessels or VSMCs, which is rescued by ATP7A overexpression. Conclusion-Akt2 plays a critical role in ATP7A protein stabilization and translocation to plasma membrane in VSMCs, which contributes to full activation of vascular SOD3 that protects against endothelial dysfunction in T2DM.
KW - Akt2 protein
KW - Copper-transporting ATPase
KW - Endothelial dysfunction
KW - Type 2 diabetes mellitus
KW - Vascular smooth muscle
UR - http://www.scopus.com/inward/record.url?scp=85051709446&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051709446&partnerID=8YFLogxK
U2 - 10.1161/ATVBAHA.117.309819
DO - 10.1161/ATVBAHA.117.309819
M3 - Article
C2 - 29301787
AN - SCOPUS:85051709446
SN - 1079-5642
VL - 38
SP - 529
EP - 541
JO - Arteriosclerosis, thrombosis, and vascular biology
JF - Arteriosclerosis, thrombosis, and vascular biology
IS - 3
ER -